Biotech Values

[jq1234]

The TNF-alpha class will be a very big FoB payday for somebody, IMO.

Agree. One company I really like is PLX. It developed cerezyme copy (via BLA) pending at FDA. It is also developing Enbrel copy. The stock has run up a lot lately, so I am not saying it is a buy right now. But watch out. From PLX website:

We are developing pr-antiTNF, a biosimilar version of etanercept (Enbrel™) using the Company's proprietary ProCellEx™ technology. pr-antiTNF is a plant cell expressed recombinant fusion protein made from the soluble form of the human TNF receptor (TNFR), fused to the Fc component of a human antibody IgG1 domain. Pr-antiTNF has an identical amino acid sequence to Enbrel™. In vitro and preclinical animal studies have demonstrated that pr-antiTNF exhibits similar activity to Enbrel™. Specifically, pr-antiTNF binds TNF alpha thereby inhibiting it from binding to cellular surface TNF receptors and protects L929 cells from TNF-induced apoptosis in a dose-dependent manner. In a proof-of-concept in vivo study using an established arthritis animal model, pr-antiTNF administered intraperitoneally significantly improved the clinical arthritis parameters associated with this accepted arthritis mouse model including joint inflammation, swelling and tissue degradation. Data from the collagen induced arthritis animal model studies are expected to be presented at an upcoming scientific conference.

http://www.protalix.com/pipeline_products.html